New, sophisticated drugs did not move the needs on hearts attacks, strokes: what this teaches us
In March, the American College of Cardiology and the American Heart Association recommended universal Lipoprotein(a) screening. However, two new drugs, ziltivekimab and pelacarsen, failed to reduce heart attacks or strokes despite targeting these biomarkers. This raises concerns about the effectiveness of advanced treatments in cardiology, highlighting a stagnation in heart disease mortality improvements.